Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) plus Kisqali (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer

Next Previous
Trial Profile

DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) plus Kisqali (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Ribociclib (Primary) ; Trastuzumab (Primary) ; Anastrozole; Capecitabine; Docetaxel; Eribulin; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin; Paclitaxel; Tamoxifen; Vinorelbine
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions
  • Acronyms DETECT V; DETECT V/CHEVENDO

    • Most Recent Events

    • 27 Jul 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Sep 2024.
    • 27 Jul 2022 Planned End Date changed from 1 Jun 2023 to 1 Nov 2024.
    • 14 Dec 2019 Until June 2019 138 patients with HER2-positive, hormone-receptor positive metastatic breast cancer have been enrolled as per trial design presented at the 42nd Annual San Antonio Breast Cancer Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top